Press Releases Sep 19, 2023 Innoviva to Participate in the Cantor Global Healthcare Conference Sep 18, 2023 XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults Aug 25, 2023 Innoviva Appoints Stephen Basso as Chief Financial Officer View all press releases Presentations & Events Cantor Global Healthcare Conference Sep 27, 2023 at 1:50 PM EDT Listen to webcast View all presentations & events Form 8937 View Form 8937 - September 30, 2015 View Form 8937
Sep 18, 2023 XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults